Department of Pharmacology, Dokuz Eylul University Medical Faculty, Izmir, Turkey.
Department of Cardiology, Dokuz Eylul University Medical Faculty, Izmir, Turkey.
Biochem Med (Zagreb). 2018 Feb 15;28(1):010901. doi: 10.11613/BM.2018.010901. Epub 2017 Nov 24.
Measurement of serum digoxin concentrations before steady-state is reached results in a falsely low concentration, and may affect treatment safety. We evaluated the proportion of serum digoxin measurements performed before steady-state is reached and the reasons for inappropriate sampling in hospitalized patients.
Electronic medical records of patients hospitalized between January 2011 and December 2015 treated with oral digoxin, that had more than one digoxin measurement were included. Serum digoxin measurements performed before achievement of pharmacological steady state were considered as inappropriate. The chi-square and chi-square for trend tests were used to analyse the relationship between inappropriate measurements and age, gender, diagnosis, inpatient service, serum digoxin, potassium and creatinine concentrations.
We evaluated 2065 hospital admissions for 1621 patients and 11,407 digoxin measurements. The time between consecutive measurements was 1.9 ± 2.4 days and 97% of all measurements were classified as inappropriate. There was no releationship between patient age, gender, serum creatinine concentration and inappropriate measurement. As opposed to expected, inappropriate digoxin measurement was higher when potassium concentrations were within the normal range (P = 0.025). Share of inappropriate determinations of digoxin was higher when concentrations > 2.6 nmol/L were recorded (P < 0.05). These measurements were requested most often in coronary care unit and cardiology department.
In our study, inappropriate serum digoxin measurement was found to be very high although only one of the appropriateness criteria was evaluated. The findings reveal the need for some strategies to prevent inappropriate measurements and reduce costs.
在达到稳态之前测量血清地高辛浓度会导致浓度偏低,并可能影响治疗安全性。我们评估了在达到稳态之前进行的血清地高辛测量比例以及住院患者中采样不当的原因。
纳入了 2011 年 1 月至 2015 年 12 月期间接受口服地高辛治疗且有多次地高辛测量的住院患者的电子病历。在达到药理稳态之前进行的血清地高辛测量被视为不适当。卡方检验和卡方趋势检验用于分析不适当测量与年龄、性别、诊断、住院科室、血清地高辛、钾和肌酐浓度之间的关系。
我们评估了 2065 例住院患者的 1621 例患者和 11407 次地高辛测量值。两次连续测量之间的时间间隔为 1.9 ± 2.4 天,97%的测量值被归类为不适当。患者年龄、性别、血清肌酐浓度与不适当测量之间没有相关性。与预期相反,当钾浓度在正常范围内时,地高辛测量不适当的比例更高(P = 0.025)。当记录的浓度>2.6 nmol/L 时,地高辛测定不适当的比例更高(P <0.05)。这些测量主要在冠心病监护病房和心脏病科进行。
在我们的研究中,尽管只评估了一个适当性标准,但发现不适当的血清地高辛测量比例非常高。这些发现表明需要采取一些策略来防止不适当的测量并降低成本。